Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis

This publication has 44 references indexed in Scilit:

• Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery?
  Journal Of Hypertension, 2005
• Global burden of hypertension: analysis of worldwide data
  The Lancet, 2005
• Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
  Journal of Human Hypertension, 2004
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
  Circulation, 2002
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
  The Lancet, 1999
• Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group.
  Stroke, 1993
• Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives
  Journal Of Hypertension, 1992
• Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study.
  Hypertension, 1991
• Low‐dose Antihypertensive Treatment with a Thiazide Diuretic Is Not Diabetogenic
  Acta Medica Scandinavica, 1986
• Cardiovascular Risk and Risk Factors in a Randomized Trial of Treatment Based on the Beta-Blocker Oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH)
  Journal Of Hypertension, 1985